trial · primary record
Infliximab
Melanoma Stage III
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 42 |
| Primary completion | 2030-06-30 |
| Primary endpoint | Proportion of patients with Steroid-Free Colitis |
| Registry ID | NCT04305145 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:39.103Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04305145
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- INFLIXIMAB · approval
- Infliximab · compound